American Journal of Cardiology
Volume 104, Issue 9 , Pages 1179-1183 , 1 November 2009

The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction

  • Stein Ørn, MD

      Affiliations

    • Division of Cardiology, Stavanger University Hospital, Stavanger, Norway
    • Institute of Internal Medicine, University of Bergen, Bergen, Norway
    • ,
  • Unni M. Breland, MD

      Affiliations

    • Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
    • Corresponding Author InformationCorresponding author: Tel: (47) 2307-3626; fax: (47) 2307-3630
    • ,
  • Tom Eirik Mollnes, MD, PhD

      Affiliations

    • Institute of Immunology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
    • ,
  • Cord Manhenke, MD

      Affiliations

    • Division of Cardiology, Stavanger University Hospital, Stavanger, Norway
    • ,
  • Kenneth Dickstein, MD, PhD

      Affiliations

    • Division of Cardiology, Stavanger University Hospital, Stavanger, Norway
    • Institute of Internal Medicine, University of Bergen, Bergen, Norway
    • ,
  • Pål Aukrust, MD, PhD

      Affiliations

    • Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
    • Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
    • ,
  • Thor Ueland, PhD

      Affiliations

    • Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
    • Department of Endocrinology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway

Received 15 April 2009 ,Revised 11 June 2009 ,Accepted 11 June 2009.

References 

  1. Kervinen H, Manttari M, Kaartinen M, Makynen H, Palosuo T, Pulkki K, et al. Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol. 2004;94:993–996
  2. de Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van der Hoeven BL, et al. CCL3 (MIP-1alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol. 2008;45:446–452
  3. Judd RM, Lugo-Olivieri CH, Arai M, Kondo T, Croisille P, Lima JA, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92:1902–1910
  4. Ørn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction. Eur Heart J. 2009;10:1180–1186
  5. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28:1909–1919
  6. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897–1908
  7. Kanda T, Hirao Y, Oshima S, Yuasa K, Taniguchi K, Nagai R, et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol. 1996;77:304–307
  8. Pannitteri G, Marino B, Campa PP, Martucci R, Testa U, Peschle C. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol. 1997;80:622–625
  9. Akasaka Y, Morimoto N, Ishikawa Y, Fujita K, Ito K, Kimura-Matsumoto M, et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol. 2006;19:588–598
  10. Kukielka GL, Smith CW, LaRosa GJ, Manning AM, Mendoza LH, Daly TJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest. 1995;95:89–103
  11. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104:1041–1050
  12. van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:251–257
  13. Koten K, Hirohata S, Miyoshi T, Ogawa H, Usui S, Shinohata R, et al. Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin Biochem. 2008;41:30–37
  14. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation. 2006;114:583–590
  15. Sheikine Y, Sirsjo A. CXCL16/SR-PSOX—a friend or a foe in atherosclerosis?. Atherosclerosis. 2008;197:487–495
  16. Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res. 2008;79:195–203
  17. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–2913
  18. Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damas JK. Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther. 2005;3:1111–1124
  19. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des. 2008;14:1205–1216
  20. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Rev. 2008;58:88–111
  21. Franke A, Lante W, Fackeldey V, Becker HP, Kurig E, Zoller LG, et al. Pro-inflammatory cytokines after different kinds of cardiothoracic surgical procedures: is what we see what we know?. Eur J Cardiothoracic Surg. 2005;28:569–575
  22. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999;43:860–878
  23. Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, Haspels I, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation. 2007;116:1931–1941
  24. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T, et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2007;27:614–620
  25. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006;6:633–643
  26. Tziakas DN, Chalikias GK, Tentes IK, Stakos D, Chatzikyriakou SV, Mitrousi K, et al. Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J. 2008;29:2713–2722
  27. Vandervelde S, van Luyn MJ, Rozenbaum MH, Petersen AH, Tio RA, Harmsen MC. Stem cell-related cardiac gene expression early after murine myocardial infarction. Cardiovasc Res. 2007;73:783–793

 This work was supported by Helse Vest Grant 911017, Bergen, Norway; the Norwegian Association of Heart and Lung Patients, Oslo, Norway; Helse og Rehabilitering Grant 2003/2/0211, Oslo, Norway; the University of Oslo, Oslo, Norway; the Norwegian Council on Cardiovascular Disease, Oslo, Norway; and the Family Blix Foundation, Oslo, Norway.

PII: S0002-9149(09)01254-5

doi: 10.1016/j.amjcard.2009.06.028

American Journal of Cardiology
Volume 104, Issue 9 , Pages 1179-1183 , 1 November 2009

Article Tools

* Image Usage & Resolution